Ozempic (for type 2 diabetes) is available in three pre-filled pen strengths in the US: 2 mg/1.5 mL pen (1.34 mg per mL) - delivers 0.25 mg or 0.5 mg doses 4 mg/3 mL pen (1.34 mg per mL) - delivers 1 mg doses 8 mg/3 mL pen (2.67 mg per mL) - delivers 2 mg doses Wegovy (for weight management) comes in single-dose pens with concentrations of 0.25 mg/0.5 mL (0.5 mg/mL), 0.5 mg/0.5 mL (1 mg/mL), 1 mg/0.5 mL (2 mg/mL), 1.7 mg/0.75 mL (2.27 mg/mL), and 2.4 mg/0.75 mL (3.2 mg/mL)
Any treatment plan involving these agents should include: Regular blood tests (glucose, HbA1c, IGF-1, lipids, liver function, renal function) Documented informed consent regarding off-label or investigational use Dietitian input to monitor nutritional status, particularly during periods of rapid weight loss or reduced appetite Reconciliation of all concomitant medicines , including over-the-counter products and supplements, to minimise interaction risks Clear escalation pathways if side effects arise, including urgent review for severe abdominal pain, dehydration, or hypoglycaemia Ongoing review by a named responsible clinician Reporting of any suspected adverse effects via the MHRA Yellow Card Scheme (yellowcard.mhra.gov.uk) Your health and safety are best protected by working transparently within the NHS or a regulated private medical setting, with full disclosure of all medicines prescribed or otherwise that you are taking
The molecular mechanisms of ferroptosis and its role in cardiovascular disease
BED is also the most prevalent ED, highlighting it as a significant concern [2]
Cataracts in diabetic patients: a review article
Associations between lifetime panic attacks, posttraumatic stress disorder, and substance use disorders in a nationally representative sample
